Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25093856 | 0.80 | PARP1 (0.36) | — | |
| SCHEMBL12438208 | 0.78 | BRD4 (0.38) | BRD4CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL13155076 | 0.78 | CCNB2 (0.51) | BRD4CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL890085 | 0.78 | TSHR (0.35) | CCNB2CDK1CCNB1CDK5CDK5R1 | |
| SCHEMBL12437101 | 0.78 | CCNB2 (0.37) | BRD4CCNB2CDK1CCNB1CDK5 | |
| SCHEMBL13122872 | 0.74 | CCNB2 (0.32) | CCNB2CDK1CCNB1CDK5CDK5R1 | |
| SCHEMBL10147094 | 0.73 | BRD4 (0.34) | BRD4 | |
| SCHEMBL10147745 | 0.72 | IKBKB (0.32) | CCNB2CDK1CCNB1CDK5CDK5R1 | |
| SCHEMBL25093853 | 0.69 | KDM5B (0.31) | — | |
| SCHEMBL10147267 | 0.69 | SCN10A (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076755-A1 | Hepatitis C Virus Inhibitors | NSUN2, HCCS, HAVCR2 | BRD4 2816/4885CCNB2 168/4885CDK1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.